The dual GIP and GLP1 receptor agonist tirzepatide: a new effective treatment for type 2 diabetes mellitus

Czech version

Authors: Vladimír Uličiansky
Published in: Diab Obez 2023; 23(45): 9-17
Category:

Overview

The incretin hormones glucose-dependent insulinotropic polypeptid (GIP) and glucagon-like peptide-1 (GLP-1) have their main physiological role in augmenting insulin secretion after their nutrient-induced secretion from the gut. Tirzepatide is a novel dual glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide- 1 receptor agonist (GLP-1 RA) developed for the treatment of type 2 diabetes. Increases insulin sensitivity, improves β-cell function, reduces food intake and increases energy expenditure. Improves metabolic flexibility and nutrient partitioning. Alters adverse event profile vs. GLP-1 RA. The mechanism of action, effectivity and safety profile of tirzepatid potentially fills important gaps in the current treatment of type 2 diabetes mellitus.

Keywords:

dual agonist GIP and GLP-1 receptor (GIP and GLP-1 RA) – glucose-dependent insulinotropic polypeptide (GIP) – glucagon-like peptide-1 (GLP-1) – type 2 diabetes mellitus (DM2T)

Sources

1. Martinka E, Uličiansky V, Mokáň M et al. Konsenzuálne terapeutické odporúčania Slovenskej diabetologickej spoločnosti pre diabetes mellitus 2. typu (2018). Forum Diab 2018; 7(1): 47–68.

2. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368(9548): 1696–1705. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(06)69705–5>.

3. Nauck MA, Meier JJ. Incretin hormones: their role in health and disease. Diabetes Obes Metab 2018; 20(Suppl 1): S5–S21. Dostupné z DOI: <https://doi.org/10.1111/DOM.13129>.

4. Nauck MA, Quast DR, Jakob Wefers J et al. The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: A pathophysiological update. Diabetes Obes Metab 2021; 23(Suppl 3): S5–S29. Dostupné z DOI: <http://dx.doi.org/10.1111/dom.14496>.

5. Ukropcová B, Klimeš I. Etiopatogenéza diabetes mellitus 2. typu. In: Hulín I (ed) et al. Patofyziológia. 7th ed. SAP : Bratislava 2009: 1016–1024. ISBN 978–80–8095–043–9.

6. Uličiansky V. Patofyziologické poznámky – diabetes mellitus 2. typu. In: Uličiansky V, Schroner Z, Galajda P et al. Diabetes mellitus v zrelom veku. Quick Print: Martin 2013: 20 - 26. ISBN 978–80–971417–1-4.

7. Bartoš V. Inkretiny. In: Pelikánová T, Bartoš V a kol. Praktická diabetologie. 6th ed. Maxdorf: Praha 2018: 49–52. ISBN 978–80–7345–559–0.

8. Nauck MA, Meier JJ. The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions. Lancet Diabetes Endocrinol 2016; 4(6): 525–536. Dostupné z DOI: <http://dx.doi.org/10.1016/S2213–8587(15)00482–9>.

9. Christensen M, Vedtofte L, Holst JJ et al. Glucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans. Diabetes 2011; 60(12): 3103–3109. Dostupné z DOI: <http://dx.doi.org/10.2337/db11–0979>.

10. Samms RJ, Coghlan MP, Sloop KW. How May GIP Enhance the Therapeutic Efficacy of GLP-1? Trends. Endocrinol Metab 2020; 31(6): 410–421. Dostupné z DOI: <http://dx.doi.org/10.1016/j.tem.2020.02.006.>

11. Nauck M, D´Aessio DA. Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction. Cardiovasc Diabetol 2022; 21(1): 169. Dostupné z DOI: <http://dx.doi.org/10.1186/s12933–022–01604–7.>.

12. Coskun T, Sloop KW, Loghin C et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Mol Metab 2018; 18: 3–14. Dostupné z DOI: https://doi.org/10.1016/J. MOLMET.2018.09.009

13. Heise T, Mari A, DeVries JH et al. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial. Lancet Diabetes Endocrinol 2022; 10(6): 418–429. Dostupné z DOI: <http://dx.doi.org/10.1016/S2213–8587(22)00085–7>.

14. Urva S, Quinlan T, Landry J et al. Effects of Renal Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide. Clin Pharmacokinet 2021; 60(8): 1049–1059. Dostupné z DOI: <http://dx.doi.org/10.1007/s40262–021–01012–2>.

15. Heiss T, De Vries JH, Urva S et al. Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes. Diabetes Care 2023; 46(5): 1–7. Dostupné z DOI: <https://doi.org/10.2337/dc22–1710>.

16. Frias JP, Nauck MA, Van J et al. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Lancet 2018; 392(10160): 2180–2193. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(18)32260–8>.

17. Frias JP, Davies MJ, Rosenstock J et al. Efficacy and safety of tirzepatide vs. semaglutide once-weekly as add-on therapy to metformin in people with type 2 diabetes (SURPASS-2). Diabetes 2021; 70 (Suppl 1):84–LB. Dostupné z DOI: <https://doi.org/10.2337/db21–84-LB>.

18. Frias JP, Davies,MJ, Rosenstock JR et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Eng J Med 2021; 385(6): 503–515. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa2107519>.

19. De Block Ch, Bailey C, Wysham C et al.Tirzepatide for the treatment of adults with type 2 diabetes: An endocrine perspective. Diabetes Obes Metab 2023; 25(1): 3–17. Dostupné z WWW: https://dompubs.onlinelibrary.wiley.com/doi/pdf/10.1111/dom.14831

20. Nowak M, Novak W, Grzeszczak W. Tirzepatide a dual GIP/GLP-1 receptor agonist – a new antidiabetic drug with potential metabolic activity in the treatment of type 2 diabetes. Endokrynol Pol 2022; 73(4): 745–754. Dostupné z DOI: <http://dx.doi.org/10.5603/EP.2022.0029>.